Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Hansa Biopharma's 2025 Reports Highlight Transformative Growth and Innovation Hansa Biopharma has released its 2025 Annual and Sustainability Reports, emphasizing significant scientific advances and a strong focus on growth amidst leadership changes.

Hansa Biopharma's 2025 Reports Highlight Transformative Growth and Innovation #Sweden #Lund #Hansa_Biopharma #imlifidase #Renée_Aguiar-Lucander

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Hansa Biopharma Unveils Transformative Achievements in Its 2025 Annual and Sustainability Reports Hansa Biopharma's 2025 Annual and Sustainability Reports celebrate a year of substantial growth and scientific advancements, reflecting strong progress in healthcare.

Hansa Biopharma Unveils Transformative Achievements in Its 2025 Annual and Sustainability Reports #Sweden #FDA_Approval #Lund #Hansa_Biopharma #imlifidase

Thiard News@F4F

@newsen.bsky.social

1 month ago

Hansa Biopharma's Imlifidase BLA Receives PDUFA Date of December 2026 Hansa Biopharma announces the PDUFA action date for imlifidase, set for December 19, 2026, signaling progress for kidney transplant options.

Hansa Biopharma's Imlifidase BLA Receives PDUFA Date of December 2026 #Sweden #FDA_Approval #Lund #Hansa_Biopharma #imlifidase

Thiard News@F4F

@newsen.bsky.social

1 month ago

Hansa Biopharma's Imlifidase BLA Receives PDUFA Date for December 2026 Hansa Biopharma's Imlifidase BLA is set for PDUFA review by the FDA on December 19, 2026, marking a significant step for kidney transplant patients.

Hansa Biopharma's Imlifidase BLA Receives PDUFA Date for December 2026 #Sweden #Lund #Hansa_Biopharma #imlifidase #IDEFIRIX

Thiard News@F4F

@newsen.bsky.social

1 month ago

Hansa Biopharma's FDA Acceptance for Innovative Imlifidase Marks a Milestone in Kidney Transplant Treatments Hansa Biopharma's biologics license application for Imlifidase has been accepted by the FDA, opening new avenues for kidney transplantation.

Hansa Biopharma's FDA Acceptance for Innovative Imlifidase Marks a Milestone in Kidney Transplant Treatments #Sweden #FDA_Approval #Lund #Hansa_Biopharma #imlifidase

Thiard News@F4F

@newsen.bsky.social

1 month ago

Hansa Biopharma's Innovative Imlifidase Receives FDA Acceptance for BLA Hansa Biopharma's biologics license application for imlifidase has been accepted by the FDA, marking a significant step for kidney transplantation treatments.

Hansa Biopharma's Innovative Imlifidase Receives FDA Acceptance for BLA #USA #FDA_Approval #Lund #Hansa_Biopharma #imlifidase

Thiard News@F4F

@newsen.bsky.social

2 months ago

Hansa Biopharma's Remarkable Financial Growth in 2025 Explained Hansa Biopharma AB reports significant financial growth in Q4 and full-year 2025, reinforcing its position in biopharmaceutical innovation.

Hansa Biopharma's Remarkable Financial Growth in 2025 Explained #Sweden #financial_results #Lund #Hansa_Biopharma #imlifidase

Thiard News@F4F

@newsen.bsky.social

2 months ago

Hansa Biopharma Reports Impressive Financial Performance for Q4 and Full Year 2025 Hansa Biopharma AB announced strong financial results for both Q4 2025 and the entire year. With revenue growth and successful product milestones, the company looks ahead to future developments in kidney transplantation.

Hansa Biopharma Reports Impressive Financial Performance for Q4 and Full Year 2025 #Sweden #FDA_Approval #Lund #Hansa_Biopharma #IDEFIRIX

Thiard News@F4F

@newsen.bsky.social

2 months ago

Hansa Biopharma Honored with the 2025 SwedenBIO Award for Groundbreaking Innovations Hansa Biopharma has been awarded the prestigious 2025 SwedenBIO Award, recognizing its significant contributions to medical science and patient care.

Hansa Biopharma Honored with the 2025 SwedenBIO Award for Groundbreaking Innovations #Sweden #Lund #Hansa_Biopharma #imlifidase #SwedenBIO

Thiard News@F4F

@newsen.bsky.social

2 months ago

Hansa Biopharma Receives the Esteemed 2025 SwedenBIO Award for Exceptional Achievements Hansa Biopharma has been honored with the 2025 SwedenBIO Award, recognizing its outstanding contributions to biotechnology and global healthcare innovation.

Hansa Biopharma Receives the Esteemed 2025 SwedenBIO Award for Exceptional Achievements #Sweden #Lund #Hansa_Biopharma #Biotech_Innovation #SwedenBIO_Award

Thiard News@F4F

@newsen.bsky.social

3 months ago

Hansa Biopharma Files for FDA Approval of Imlifidase to Aid Kidney Transplant Patients Hansa Biopharma has submitted a Biologics License Application to the FDA for Imlifidase, designed to help heavily sensitized kidney transplant patients. This therapy could revolutionize patient options.

Hansa Biopharma Files for FDA Approval of Imlifidase to Aid Kidney Transplant Patients #Sweden #Lund #kidney_transplant #Hansa_Biopharma #imlifidase

Thiard News@F4F

@newsen.bsky.social

3 months ago

Hansa Biopharma's Application for Imlifidase Could Transform Kidney Transplantation for Sensitized Patients Hansa Biopharma has submitted a Biologics License Application for Imlifidase, potentially changing the game for highly sensitized kidney transplant patients in the U.S.

Hansa Biopharma's Application for Imlifidase Could Transform Kidney Transplantation for Sensitized Patients #USA #Lund #Hansa_Biopharma #imlifidase #kidney_transplantation

Thiard News@F4F

@newsen.bsky.social

5 months ago

Hansa Biopharma Unveils Third Quarter Financial Results for 2025 Hansa Biopharma announces its financial report for Q3 2025, showcasing significant milestones in kidney transplantation and promising growth in product sales.

Hansa Biopharma Unveils Third Quarter Financial Results for 2025 #Sweden #Lund #Hansa_Biopharma #imlifidase #ConfIdeS_Trial

Thiard News@F4F

@newsen.bsky.social

5 months ago

Hansa Biopharma Achieves Key Milestone in Kidney Transplantation with Imlifidase Hansa Biopharma recently reported strong interim financial results for 2025, showcasing their groundbreaking treatment Imlifidase in kidney transplantation.

Hansa Biopharma Achieves Key Milestone in Kidney Transplantation with Imlifidase #Sweden #Lund #Hansa_Biopharma #imlifidase #kidney_transplantation

Thiard News@F4F

@newsen.bsky.social

5 months ago

Hansa Biopharma Hosts Virtual Event with Renowned Transplant Surgeons Focusing on Imlifidase Phase 3 Results Join Hansa Biopharma for an insightful session featuring leading transplant surgeons discussing the Phase 3 results of Imlifidase, a novel treatment for transplant patients.

Hansa Biopharma Hosts Virtual Event with Renowned Transplant Surgeons Focusing on Imlifidase Phase 3 Results #Sweden #Lund #Hansa_Biopharma #imlifidase #Transplant_Surgeons

Thiard News@F4F

@newsen.bsky.social

5 months ago

Hansa Biopharma Hosts Virtual Event with Leading Transplant Surgeons to Discuss Imlifidase Phase 3 Results Hansa Biopharma's upcoming virtual event on November 12, 2025, will involve insights from top transplant surgeons regarding the Phase 3 results of imlifidase.

Hansa Biopharma Hosts Virtual Event with Leading Transplant Surgeons to Discuss Imlifidase Phase 3 Results #Sweden #Lund #Hansa_Biopharma #imlifidase #Transplant_Surgeons

Thiard News@F4F

@newsen.bsky.social

6 months ago

Imlifidase Shows Promising Results in Critical Phase 3 Kidney Transplant Trial Hansa Biopharma's imlifidase meets primary endpoint in US Phase 3 ConfIdeS trial, benefitting kidney transplantation for highly sensitized patients.

Imlifidase Shows Promising Results in Critical Phase 3 Kidney Transplant Trial #USA #Lund #Hansa_Biopharma #imlifidase #ConfIdeS_Trial

Thiard News@F4F

@newsen.bsky.social

8 months ago

Hansa Biopharma Strengthens Leadership Team with New Executive Roles Hansa Biopharma has appointed three key executives to drive growth, enhancing its expertise in legal, HR, and corporate affairs sectors.

Hansa Biopharma Strengthens Leadership Team with New Executive Roles #Sweden #Leadership #Lund #Hansa_Biopharma #Corporate_Affairs

Thiard News@F4F

@newsen.bsky.social

8 months ago

Hansa Biopharma Expands Leadership Team to Enhance Growth Strategy and Operations Hansa Biopharma has welcomed three new executive leaders to its team, aiming to accelerate growth and bolster its operations in the biopharmaceutical sector.

Hansa Biopharma Expands Leadership Team to Enhance Growth Strategy and Operations #Sweden #Lund #Hansa_Biopharma #Corporate_Affairs #Brian_Gorman

Thiard News@F4F

@newsen.bsky.social

8 months ago

Hansa Biopharma Achieves Strong Financial Growth and Pipeline Progress in Q2 2025 Hansa Biopharma's Q2 2025 results reflect significant sales growth and strategic financing, focusing on critical Phase 3 trials in transplantation.

Hansa Biopharma Achieves Strong Financial Growth and Pipeline Progress in Q2 2025 #Sweden #financial_results #Lund #Hansa_Biopharma #IDEFIRIX

Thiard News@F4F

@newsen.bsky.social

8 months ago

Hansa Biopharma Reports Significant Financial Progress in Q2 2025 Hansa Biopharma has shared its impressive interim financial results for the first half of 2025, reflecting strong sales growth and strategic advancements in their pipeline.

Hansa Biopharma Reports Significant Financial Progress in Q2 2025 #Sweden #Lund #Hansa_Biopharma #IDEFIRIX #Phase_3_Trials

Thiard News@F4F

@newsen.bsky.social

9 months ago

Hansa Biopharma Welcomes Dr. Richard Philipson as Chief Medical Officer to Enhance Drug Development Strategy Hansa Biopharma has appointed Dr. Richard Philipson as Chief Medical Officer, bringing over 25 years of experience in drug development and clinical leadership.

Hansa Biopharma Welcomes Dr. Richard Philipson as Chief Medical Officer to Enhance Drug Development Strategy #Sweden #Lund #Hansa_Biopharma #Chief_Medical_Officer #Richard_Philipson

Thiard News@F4F

@newsen.bsky.social

9 months ago

Hansa Biopharma Welcomes Dr. Richard Philipson as New CMO to Lead Drug Development Hansa Biopharma has appointed Dr. Richard Philipson as its new Chief Medical Officer. His extensive experience is expected to advance the company's drug development initiatives.

Hansa Biopharma Welcomes Dr. Richard Philipson as New CMO to Lead Drug Development #Sweden #Lund #Hansa_Biopharma #Chief_Medical_Officer #Dr._Philipson

Thiard News@F4F

@newsen.bsky.social

9 months ago

Hansa Biopharma Reveals Promising Five-Year Data on Imlifidase in Kidney Transplants at ESOT 2025 At the ESOT Congress 2025, Hansa Biopharma presented five-year results from its imlifidase study, signaling great potential for kidney transplant success in sensitized patients.

Hansa Biopharma Reveals Promising Five-Year Data on Imlifidase in Kidney Transplants at ESOT 2025 #Sweden #Lund #kidney_transplant #Hansa_Biopharma #imlifidase

Thiard News@F4F

@newsen.bsky.social

9 months ago

Hansa Biopharma Unveils Five-Year Follow-Up Results for Imlifidase in Kidney Transplants at ESOT 2025 Hansa Biopharma showcases exciting five-year data on imlifidase for kidney transplants, demonstrating promising patient outcomes at ESOT 2025 in London.

Hansa Biopharma Unveils Five-Year Follow-Up Results for Imlifidase in Kidney Transplants at ESOT 2025 #Sweden #London #Hansa_Biopharma #imlifidase #ESOT_Congress

Thiard News@F4F

@newsen.bsky.social

10 months ago

Hansa Biopharma Set to Showcase Innovations at BIO International Convention 2025 Join Hansa Biopharma's CEO, Renée Aguiar-Lucander, as she addresses the BIO International Convention 2025 in Boston, discussing biotech investments.

Hansa Biopharma Set to Showcase Innovations at BIO International Convention 2025 #Sweden #Lund #Hansa_Biopharma #Renée_Aguiar-Lucander #biotech_investment

Thiard News@F4F

@newsen.bsky.social

10 months ago

Hansa Biopharma's CEO to Speak at the Upcoming BIO International Convention in Boston Hansa Biopharma's CEO will be addressing key issues in biotechnology at the BIO International Convention, highlighting investment opportunities in Europe.

Hansa Biopharma's CEO to Speak at the Upcoming BIO International Convention in Boston #Sweden #Lund #Hansa_Biopharma #BIO_Convention #Renée_Aguiar-Lucander

Thiard News@F4F

@newsen.bsky.social

11 months ago

Hansa Biopharma Unveils Promising Findings on Imlifidase for Guillain-Barré Syndrome at 2025 PNS Annual Meeting At the 2025 PNS Annual Meeting in Edinburgh, Hansa Biopharma reveals groundbreaking data on imlifidase's effectiveness for Guillain-Barré Syndrome treatment, showcasing its potential.

Hansa Biopharma Unveils Promising Findings on Imlifidase for Guillain-Barré Syndrome at 2025 PNS Annual Meeting #Sweden #Lund #Hansa_Biopharma #imlifidase #GBS_Treatment

Thiard News@F4F

@newsen.bsky.social

11 months ago

Hansa Biopharma Showcases Imlifidase's Promise in Guillain-Barré Syndrome at 2025 PNS Meeting At the 2025 PNS Annual Meeting, Hansa Biopharma unveiled promising data on imlifidase, showcasing its potential in treating Guillain-Barré Syndrome.

Hansa Biopharma Showcases Imlifidase's Promise in Guillain-Barré Syndrome at 2025 PNS Meeting #Sweden #Lund #Hansa_Biopharma #imlifidase #Guillain-Barré

Thiard News@F4F

@newsen.bsky.social

11 months ago

Hansa Biopharma Welcomes Maria Törnsén as New COO and U.S. President Hansa Biopharma has appointed Maria Törnsén as the new Chief Operating Officer and President for the U.S., effective May 19, 2025.

Hansa Biopharma Welcomes Maria Törnsén as New COO and U.S. President #Sweden #Lund #Hansa_Biopharma #IDEFIRIX #Maria_Törnsén